


In the claims:

1. (Original) A compound of Formula I:



wherein:

R^{1a} and R^{1b} are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C₁-C₁₀ alkyl,
- 3) OR³,
- 4) N(R³)₂,
- 5) unsubstituted or substituted aryl,
- 6) unsubstituted or substituted heterocycle, and
- 7) unsubstituted or substituted C₃-C₁₀ cycloalkyl;

R^{1c} is independently selected from:

- 1) hydrogen,
- 2) C₁-C₁₀ alkyl,
- 3) OR³,
- 4) N(R³)₂,
- 5) C₃-C₁₀ cycloalkyl,
- 6) aryl, and
- 7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R⁷;

R² is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C₁-C₁₀ alkyl,
- 3) N(R³)₂,
- 4) OR³,
- 5) unsubstituted or substituted aryl, and
- 6) unsubstituted or substituted C₃-C₁₀ cycloalkyl;

R³ is independently selected from:

- 1) hydrogen,
- 2) C₁-C₁₀ alkyl,
- 3) aryl,
- 4) heterocycle,
- 5) C₃-C₁₀ cycloalkyl,
- 6) CF₃,
- 7) C₂-C₆ alkenyl,
- 8) C₂-C₆ alkynyl,
- 9) S(O)_mR⁶, and
- 10) C(O)R⁶;

said alkyl, cycloalkyl, aryl, heterocycle, alkynyl, and alkenyl is optionally substituted with at least one substituent selected from R⁷;

R⁵ is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) -(CR¹C₂)_nOR³,
- 4) -(CR¹C₂)_nR⁶,
- 5) -C(O)OR³,
- 6) -C(O)R³,
- 7) -C≡CR³,

- 8) $-R^3C=C(R^3)_2$,
- 9) $-OS(O)_mR^6$,
- 10) $-NO_2$,
- 11) $-(CR^{1c}_2)_nN(R^3)_2$,
- 12) $-N(R^3)C(O)R^3$,
- 13) $-N(R^3)S(O)_mR^6$,
- 14) $-(CR^{1c}_2)_nNR^3(CR^{1c}_2)_nC(O)NR^3_2$,
- 15) $-O(CR^{1c}_2)_nC(O)N(R^3)_2$,
- 16) $-O(CR^{1c}_2)_nC(O)OR^3$,
- 17) $-NR^3(CR^{1c}_2)_nN(R^3)_2$,
- 18) $-(CR^{1c}_2)_nNR^3R^6OR^3$,
- 19) $-S(O)_mR^6$,
- 20) $-S(O)_mN(R^3)_2$,
- 21) $-CN$,
- 22) $-(CR^{1c}_2)_nN(R^3)(CR^{1c}_2)_nR^6$, and
- 23) $-(CR^{1c}_2)_nC(O)N(R^3)_2$;

R^6 is independently selected from:

- 1) C_1 - C_{10} alkyl,
- 2) C_3 - C_{10} cycloalkyl,
- 3) aryl, and
- 4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7 ;

R^7 is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C_1 - C_{10} alkyl,
- 3) unsubstituted or substituted C_3 - C_{10} cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) halogen,
- 6) OR^3 ,

- 7) CF_3 ,
- 8) unsubstituted or substituted heterocycle,
- 9) $\text{S(O)}_m\text{N(R}^3)_2$,
- 10) C(O)OR^3 ,
- 11) C(O)R^3 ,
- 12) CN ,
- 13) $\text{C(O)N(R}^3)_2$,
- 14) $\text{N(R}^3)\text{C(O)R}^3$,
- 15) $\text{S(O)}_m\text{R}^6$, and
- 16) NO_2 ;

Y and Z are independently selected from:

- 1) hydrogen,
- 2) R^6 ,
- 3) OR^3 ,
- 4) $\text{N(R}^3)_2$,
- 5) C(O)OR^3 ,
- 6) $\text{C(O)N(R}^3)_2$,
- 7) C(O)R^3 ,
- 8) halogen,
- 9) $\text{N(R}^3)(\text{CR}^{1c_2})_n\text{C(O)N(R}^3)_2$,
- 10) $\text{S(O)}_m\text{N(R}^3)_2$,
- 11) $\text{N(R}^3)\text{C(O)OR}^3$,
- 12) $\text{N(R}^3)\text{S(O)}_m\text{R}^6$,
- 13) $\text{N(R}^3)\text{C(O)R}^3$,
- 14) $\text{N(R}^3)(\text{CR}^{1c_2})_n\text{R}^3$,
- 15) $\text{S(O)}_m\text{R}^6$,
- 16) $\text{R}^6\text{S(O)}_m\text{N(R}^3)_2$,
- 17) $\text{R}^6\text{S(O)}_m\text{R}^6$,
- 18) $\text{N(R}^3)\text{S(O)}_m(\text{CR}^{1c_2})_n\text{R}^6$,
- 19) $\text{N(R}^3)\text{S(O)}_m\text{R}^6\text{OR}^3$,
- 20) $\text{N(R}^3)\text{C(O)N(R}^3)_2$,

- 21) $N(R^3)C(O)R^6OR^3$,
- 22) $N(R^3)(CR^{1c}2)_nR^6OR^3$,
- 23) $N(R^3)OR^3$, and
- 24) $N(R^3)S(O)_mR^6NO_2$;

m is independently 0, 1 or 2;

n is independently 0 to 6;

s is 0 to 6;

t is 0 to 6;

w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Original) The compound according to Claim 1,
wherein:

R^{1a} and R^{1b} are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C_1 - C_{10} alkyl,
- 3) unsubstituted or substituted aryl,
- 4) unsubstituted or substituted heterocycle, and
- 5) OR^3 ;

R^{1c} is independently selected from:

- 1) hydrogen,
- 2) C_1 - C_{10} alkyl,
- 3) OR^3 ,
- 4) $N(R^3)_2$,
- 5) aryl, and
- 6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7 ;

R^2 is:

- 1) H,

- 2) unsubstituted or substituted alkyl,
- 3) OR^3 , or
- 4) $N(R^3)_2$;

R^3 is independently selected from:

- 1) hydrogen,
- 2) C_1 - C_{10} alkyl,
- 3) aryl,
- 4) heterocycle,
- 5) C_3 - C_{10} cycloalkyl,
- 6) CF_3 ,
- 7) $S(O)_mR^6$, and
- 8) $C(O)R^6$;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7 ;

R^5 is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) $-OR^3$,
- 4) $-C(O)OR^3$,
- 5) $-C(O)R^3$,
- 6) $-C\equiv CR^3$,
- 7) $-R^3C=C(R^3)_2$,
- 8) $-OS(O)_mR^6$,
- 9) $-NO_2$,
- 10) $-N(R^3)_2$,
- 11) $-N(R^3)C(O)R^3$,
- 12) $-N(R^3)S(O)_mR^6$,
- 13) $-(CR^{1c}_2)_nNR^3(CR^{1c}_2)_nC(O)NR^3_2$,
- 14) $-O(CR^{1c}_2)_nC(O)N(R^3)_2$,
- 15) $-O(CR^{1c}_2)_nC(O)OR^3$,

- 16) $-\text{NR}^3(\text{CR}^{1c_2})_n\text{N}(\text{R}^3)_2$,
- 17) $-(\text{CR}^{1c_2})_n\text{NR}^3\text{R}^6\text{OR}^3$,
- 18) $-\text{S}(\text{O})_m\text{R}^6$,
- 19) $-\text{S}(\text{O})_m\text{N}(\text{R}^3)_2$,
- 20) $-\text{CN}$, and
- 21) $-(\text{CR}^{1c_2})_n\text{N}(\text{R}^3)(\text{CR}^{1c_2})_n\text{R}^6$;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Original) The compound according to Claim 2,
wherein:

R^{1a} and R^{1b} are independently selected from hydrogen, unsubstituted or substituted C_1 - C_{10} alkyl, OR^3 , and unsubstituted or substituted aryl;

R^{1c} is independently selected from:

- 1) hydrogen,
- 2) C_1 - C_{10} alkyl,
- 3) OR^3 , and
- 4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R^7 ;

R^2 is:

- 1) OR^3 , or
- 2) $\text{N}(\text{R}^3)_2$;

R^5 is independently selected from:

- 1) hydrogen,
- 2) $(\text{CR}^{1c_2})_n\text{R}^6$,
- 3) halogen,
- 4) $-(\text{CR}^{1c_2})_n\text{OR}^3$,
- 5) $-\text{C}(\text{O})\text{OR}^3$,
- 6) $-\text{C}(\text{O})\text{R}^3$,

- 7) $-\text{C}\equiv\text{CR}^3$,
- 8) $-\text{R}^3\text{C}=\text{C}(\text{R}^3)_2$,
- 9) $(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{N}(\text{R}^3)_2$, and
- 10) $(\text{CR}^1\text{c}_2)_n\text{N}(\text{R}^3)_2$;

Y is:

- 1) hydrogen,
- 2) R^6 ,
- 3) OR^3 ,
- 4) $\text{C}(\text{O})\text{R}^3$,
- 5) $\text{C}(\text{O})\text{N}(\text{R}^3)_2$, or
- 6) $\text{N}(\text{R}^3)_2$;

Z is:

- 1) hydrogen,
- 2) R^6 ,
- 3) OR^3 ,
- 4) $\text{N}(\text{R}^3)_2$,
- 5) $\text{C}(\text{O})\text{OR}^3$,
- 6) $\text{C}(\text{O})\text{N}(\text{R}^3)_2$,
- 7) $\text{C}(\text{O})\text{R}^3$,
- 8) halogen,
- 9) $\text{N}(\text{R}^3)(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{N}(\text{R}^3)_2$,
- 10) $\text{S}(\text{O})_m\text{N}(\text{R}^3)_2$,
- 11) $\text{N}(\text{R}^3)\text{C}(\text{O})\text{OR}^3$,
- 12) $\text{N}(\text{R}^3)\text{S}(\text{O})_m\text{R}^6$,
- 13) $\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$,
- 14) $\text{N}(\text{R}^3)(\text{CR}^1\text{c}_2)_n\text{R}^3$, or
- 15) $\text{S}(\text{O})_m\text{R}^6$;

n is independently 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Original) A compound selected from:

5-Chloro-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;

3-(Aminosulfonyl)-5-chloro-1*H*-indole-2-carboxamide;

5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3 yl)methyl] amino}
sulfonyl)-1*H*-indole-2-carboxamide;

3-({ [2-(Aminosulfonyl)ethyl]amino } sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;
3-[(Dimethylamino)sulfonyl]-5-methoxy-1*H*-indole-2-carboxamide;

5-Chloro-3- { [(2-phenethyl)amino]sulfonyl } -1*H*-indole-2-carboxamide;

5-Chloro-3-[(benzylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclohexylamino)sulfonyl]-1*H*-indole-2-carboxamide ;

5-Chloro-3-[(1-naphthylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3- { [(3-phenylpropyl)amino]sulfonyl } -1*H*-indole-2-carboxamide;

5-Chloro-3-[(ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(propylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(butylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pentylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3- { [ethyl(methyl)amino]sulfonyl } -1*H*-indole-2-carboxamide;

5-Chloro-3-[(diethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(*iso*-propylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclobutylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclopentylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(4-chlorophenyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(3-chlorophenyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(2-chlorophenyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(4-chlorophenyl)methylamino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(3-chlorophenyl)methylamino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(2-chlorophenyl)methylamino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(*tert*-butylamino)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(1-methyl-1*H*-benzimidazol-2-yl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(benzamideamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(2-methoxyethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(dimethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

3-([2-(Aminosulfonyl)ethyl]amino)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;

5-Chloro-3-[[(2-hydroxyethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3- {[(2-morpholin-4-ylethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
5-Chloro-3- {[(2-methoxyethyl)(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
5-Bromo-3- [({[2-(2-acetamide)amino]ethyl} amino)sulfonyl] -1*H*-indole-2-carboxamide;
N- {[2-(Aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl} -*N*-methyl-β-alaninamide;
5-Bromo-3- [(methylamino)sulfonyl] -1*H*-indole-2-carboxamide;
Ethyl *N*- {[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl} *N*-methyl-β-alaninate;
5-Bromo-3- {[cyclopropyl(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
(±)-5-Bromo-3- {[methyl(tetrahydrofuran-3-yl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
5-Bromo-3- ({methyl[2-(1*H*-1,2,4-triazol-1-yl)ethyl]amino} sulfonyl) -1*H*-indole-2-carboxamide;
5-Bromo-3- {[methyl(tetrahydro-2*H*-pyran-4-yl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
(±)-5-Bromo-3- {[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
3- ({ [4-(Aminosulfonyl)benzyl]amino} sulfonyl) -5-bromo-1*H*-indole-2-carboxamide;
5-Chloro-3- {[*iso*-propyl(2-methoxyethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
3- {[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl} -5-hydroxy-1*H*-indole-2-carboxamide;
3- {[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl} -5-methoxy-1*H*-indole-2-carboxamide;
5-Chloro-3- {[methoxy(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;
(±)-5-Chloro-3- {[(2,3-dihydroxypropyl)(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycine;
N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycinamide;
5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;
3-[(2-[4-(Aminosulfonyl)phenyl]ethyl)amino]sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
3-{[(5-Amino-5-oxopentyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;
3-({[2-(Aminosulfonyl)ethyl]amino} sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;
tert-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl} amino)-ethylcarbamate;
3-{[(2-Aminoethyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;
5-Bromo-3-[({ethylsulfonylamino} ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
5-Iodo-3-{[(2- {[(4-methoxyphenyl)sulfonyl]amino} ethyl)amino]sulfonyl}-1 *H*-indole-2-carboxamide;
5-Bromo-3- {[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
5-Fluoro-3- {[(2- {[(4-methoxyphenyl)sulfonyl]amino} ethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
5-Bromo-3- {[(2- {[(4-nitrophenyl)sulfonyl]amino} ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
5-Bromo-3- ({[2- ({[(4-methoxyphenyl)amino]carbonyl} amino)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;
5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl} amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-[(4-chlorophenyl)thio]propyl)amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3-[(3-[(4-chlorophenyl)sulfonyl]propyl)amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3-[(propylsulfonylamino)ethylamino)sulfonyl]-1 *H*-indole-2-carboxamide
hydrochloride;

5-Bromo-3-[(2-[(4-methoxyphenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-indole-2-
carboxamide ;

5-Bromo-3-[(2-[(phenylsulfonyl)amino]ethyl)amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(methylsulfonyl)amino]ethyl)amino)sulfonyl]-1 *H*-indole-2-carboxamide;

3-[(2-[(Benzylsulfonyl)amino]ethyl)amino)sulfonyl]-5-bromo-1 *H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(3-methoxyphenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-indole-2-
carboxamide;

5-Bromo-3-[(2-[(2,5-dimethoxyphenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-indole-2-
carboxamide;

5-Bromo-3-[(2-[(5-bromo-2-methoxyphenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-
indole-2-carboxamide;

5-Bromo-3-[(2-[(2-(trifluoromethoxy)phenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-
indole-2-carboxamide;

5-Bromo-3-[(2-[(2-methoxy-5-methylphenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-
indole-2-carboxamide;

5-Bromo-3-[(2-[(4-cyanophenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-indole-2-
carboxamide;

5-Bromo-3-[(2-[(4-chlorophenyl)sulfonyl]amino)ethylamino)sulfonyl]-1 *H*-indole-2-
carboxamide;

5-Bromo-3-{{(2-{{(3,4-dimethoxyphenyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-[(phenylsulfonyl)amino]propyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(3-{{(4-methoxyphenyl)sulfonyl}amino}propyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

3-[(3-[(Benzylsulfonyl)amino]propyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

3-[(2-[(Aminocarbonyl)amino]ethyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(2-{{(4-bromophenyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(thien-3-ylsulfonyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(2-{{(3-chlorobenzyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(2-{{(2-phenylethyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxybenzoyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxybenzyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxyphenyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

3-[(2-[Acetyl(4-methoxyphenyl)amino]ethyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Iodo-3-[(cyclopropyl(methyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1-*H*-indole-2-carboxamide;

5-chloro-3-{[methyl(tetrahydro-2*H*-pyran-4-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-chloro-3-({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-[(tetrahydro-2*H*-pyran-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-chloro-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-chloro-3-({[(3-methyloxetan-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-[(tetrahydrofuran-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-chloro-3-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[2-(2-methoxyphenyl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[3-(trifluoromethyl)benzyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[2-(2,3-dihydro-1*H*-indol-1-yl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({methyl[(1-methylpiperidin-3-yl)methyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl] amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-bromo-3-({[(3-ethoxypropyl) amino] sulfonyl}-1*H*-indole-2-carboxamide;

3-[({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl] sulfonyl} amino) methyl]-1-benzylpyrrolidine;

5-bromo-3-({[(1-benzylpyrrolidin-3-yl)methyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-bromo-3-({[(3-pyridin-3-ylpropyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

1-[2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl] sulfonyl} amino)ethyl]-4-phenylpiperidine;

5-bromo-3-({[(3-cyclohexylpropyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-bromo-3-({[(4,4-diphenylbutyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-bromo-3-({[(3-butoxypropyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-bromo-3-({[(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-7-yl)methyl]amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-bromo-3-({[3-(3,5-dimethyl-1*H*-pyrazol-1-yl)propyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-bromo-3-({[4-(4-tert-butoxyphenyl)butyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[(2-methoxy-1-methylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-({[(4-phenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-[(2-[(2,6-dichlorobenzyl)thio]ethyl)amino]sulfonyl]-1H-indole-2-carboxamide;


5-bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-[(6-[(4-chlorobenzyl)amino]-6-oxohexyl)amino]sulfonyl]-1H-indole-2-carboxamide;


or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Original) The compound according to Claim 4, that is selected from:


5-Chloro-3-({[ethyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide




(±)-5-Bromo-3-({[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1H-indole-2-carboxamide




3-({[2-(Aminosulfonyl)ethyl]amino} sulfonyl)-5-bromo-1*H*-indole-2-carboxamide




5-Bromo-3-{{(2-{{[(4-methoxyphenyl)sulfonyl]amino} ethyl]amino} sulfonyl)}-1*H*-indole-2-carboxamide




5-bromo-3-{{[(3-butoxypropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide



5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino} sulfonyl)-1*H*-indole-2-carboxamide



5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

7. (Original) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

8. (Original) The method of Claim 7 wherein the protein kinase is an RTK.

9. (Original) The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.

10. (Original) A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

11. (Original) A method of Claim 10, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,
- 5) aging,
- 6) acromegaly, and
- 7) Crohn's disease.

12. (Original) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. (Original) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

14. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second

compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) an angiogenesis inhibitor.

15. (Original) The method of Claim 14, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

16. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

17. (Original) The method of Claim 16 wherein radiation therapy is also administered.

18. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

19. (Original) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

20. (Canceled)

21. (Canceled)

22. (Original) A process for preparing an alkyl 5-iodo-1*H*-indole-2-carboxylate which comprises the steps of:

- a) combining alkyl 1*H*-indole-2-carboxylate, iodine, sodium periodate and sulfuric acid in an alcohol, and heating to a temperature of about 50 °C to about 100 °C to obtain a product;
- b) adding the product to a solution of organic solvent and aqueous solution to create a first biphasic mixture;
- c) removing, drying, filtering and concentrating the organic layer;
- d) dissolving the organic layer in an alcohol;
- e) adding zinc and aqueous acid to produce a mixture;
- f) combining the mixture with water to create a second biphasic mixture; and
- g) extracting, drying and filtering the organic layer of the second biphasic mixture to obtain the alkyl 5-iodo-1*H*-indole-2-carboxylate.

23. (Original) The process of Claim 22 wherein the alkyl 5-iodo-1*H*-indole-2-carboxylate is ethyl 5-iodo-1*H*-indole-2-carboxylate.